Trial Profile

ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2025 According to Clearside Biomedical Media Release, data from this trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting.
24 Mar 2025 According to Clearside Biomedical Media Release, top line results from this study accepted for presentation at association for research in vision and phthalmology (ARVO) 2025 Meeting.
06 Mar 2025 According to Clearside Biomedical Media Release, the company announced positive outcome of End-of-Phase 2 meeting with the FDA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com